• Japanese
  • Korean
  • Chinese
Cover Image

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

Summary

"PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013" applies GlobalData's proprietary ranking methodology to compare the competitive position of 30 generic pharmaceutical companies across various markets on 12 financial metrics. The performances of these companies are analyzed based on financial performance, cost-containment, capital structure, and efficiency to illustrate the different strategies these companies are using to increase shareholder value and capture market share from branded pharmaceuticals manufacturers. In addition to the financial metrics, this report presents SWOT analyses of the major players, and describes the operations strategy of these companies.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.

Scope

  • The report provides analysis of the key drivers and trends shaping the global generics industry.
  • The report identifies the key generic players in various markets, including a special focus on emerging markets such as India, China, Russia, and Brazil.
  • Furthermore, it provides detailed analysis of the various generic markets including the US, Europe, APAC, and BRIC.
  • The report contains expert insights on the corporate strategies of generic companies seeking competitive advantage in the highly competitive generics industry.

Reasons to buy

  • Benchmark your company's performance against other generic pharmaceutical companies to identify strengths that can be leveraged and/or areas of possible improvement
  • Analyze and track the strategies that successful generic pharmaceutical companies are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending, asset structure, and efficiency
  • Use this information as an independent source for your due diligence and transaction strategy

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Upcoming Related Reports
  • 2.3. Recently Published Reports
  • 2.4. GlobalData's Benchmarking Methodology

3. GlobalData Benchmark Rankings

  • 3.1. Sun Pharmaceuticals Emerges as Generics Leader

4. Financial Management

  • 4.1. Competitive Framework
  • 4.2. Overview
  • 4.3. Financial Management: Heat Map
  • 4.4. Financial Metrics
    • 4.4.1. Revenue Leaders
    • 4.4.2. Revenue Laggards
    • 4.4.3. Revenue Growth Leaders
    • 4.4.4. Revenue Growth Laggards
    • 4.4.5. Operating Income Leaders
    • 4.4.6. Operating Income Laggards
    • 4.4.7. Operating Income YTY Growth Leaders
    • 4.4.8. Operating Income YTY Growth Laggards
    • 4.4.9. Operating Margin Leaders
    • 4.4.10. Operating Margin Laggards

5. Expense Management

  • 5.1. Competitive Framework
  • 5.2. Overview
  • 5.3. Expense Management: Heat Map
  • 5.4. Expense Metrics
    • 5.4.1. SG&A Spending Leaders
    • 5.4.2. SG&A Spending Laggards
    • 5.4.3. SG&A YTY Change Leaders
    • 5.4.4. SG&A YTY Change Laggards
    • 5.4.5. Operating Expense Leaders
    • 5.4.6. Operating Expense Laggards

6. Capital Management

  • 6.1. Competitive Framework
  • 6.2. Overview
  • 6.3. Competitive Framework: Heat Map
  • 6.4. Capital Management Metrics
    • 6.4.1. Debt-to-Assets Leaders
    • 6.4.2. Debt-to-Assets Laggards
    • 6.4.3. Cash Ratio Leaders
    • 6.4.4. Cash Ratio Laggards
    • 6.4.5. ROI Leaders
    • 6.4.6. ROI Laggards

7. Key Players

  • 7.1. Strategic Analysis of Leading Generics Players
    • 7.1.1. Sun Pharmaceuticals: The Benchmark Leader
    • 7.1.2. Sandoz
    • 7.1.3. Pharmstandard
    • 7.1.4. Teva Pharmaceuticals
    • 7.1.5. Actavis
    • 7.1.6. Mylan
    • 7.1.7. Ranbaxy
    • 7.1.8. Dr. Reddy's
    • 7.1.9. Covidien
    • 7.1.10. Hospira

8. Outlook

  • 8.1. Leverage Improvement will Significantly Alter 2013 Benchmark Rankings
  • 8.2. Generic Manufacturers in Emerging Markets will continue to Challenge for Top Spots

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
    • 9.3.3. Expert Panel Validation
  • 9.4. About the Authors
    • 9.4.1. Analyst
    • 9.4.2. Director of Healthcare Industry Dynamics
    • 9.4.3. Global Head of Healthcare Research and Consulting
  • 9.5. About the Industry Dynamics Team
  • 9.6. About GlobalData
  • 9.7. Contact Us
  • 9.8. Disclosure Information
  • 9.9. Disclaimer

List of Tables

  • Table 1: GlobalData Benchmark Rankings, FY2012
  • Table 2: Top 15 Companies FM Composite Scores and Overall FM Score, 2012
  • Table 3: Bottom 15 Companies' FM Composite Scores and Overall FM Score, 2012
  • Table 4: FY2012 Top Three Revenue Leaders
  • Table 5: FY2012 Top Three Revenue Laggards
  • Table 6: FY2012 Top Three Revenue Growth Leaders
  • Table 7: FY2012 Top Three Revenue Growth Laggards
  • Table 8: FY2012 Top Three Operating Income Leaders
  • Table 9: FY2012 Top Three Operating Income Laggards
  • Table 10: FY2012 Top Three YTY Operating Income Growth Leaders
  • Table 11: FY2012 Top Three YTY Operating Income Growth Laggards
  • Table 12: FY2012 Top Three Operating Margin Leaders
  • Table 13: FY2012 Top Three Operating Margin Laggards
  • Table 14: Top 15 Companies' EM Composite Scores and Overall EM Score, 2012
  • Table 15: Bottom 15 Companies' EM Composite Scores and Overall EM Score, 2012
  • Table 16: FY2012 Top SG&A Spending Leaders as a Percentage of Revenue
  • Table 17: FY2012 Top R&D Spending Laggards as a Percentage of Revenue
  • Table 18: FY2012 Top SG&A YTY Change Leaders
  • Table 19: FY2012 Top SG&A YTY Change Laggards
  • Table 20: FY2012 Top Operating Expense Leaders as a Percentage of Revenue
  • Table 21: FY2012 Top Operating Expense Laggards as a Percentage of Revenue
  • Table 22: Top 15 Companies' CM Composite Scores and Overall CM Score, 2012
  • Table 23: Bottom 15 Companies' CM Composite Scores and Overall CM Score, 2012
  • Table 24: FY2012 Top Debt-to-Assets Leaders
  • Table 25: FY2012 Debt-to-Assets Laggards
  • Table 26: FY2012 Cash Ratio Leaders
  • Table 27: FY2012 Cash Ratio Laggards
  • Table 28: FY2012 ROI Leaders
  • Table 29: FY2012 ROI Laggards

List of Figures

  • Figure 1: Generics Manufacturing Landscape Assessment - FY2012 Corporate Revenue Growth vs. Operating Margin
  • Figure 2: Generics Manufacturing Landscape Assessment - FY2012 Generics Sales Growth vs. Operating Margin
  • Figure 3: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Revenue
  • Figure 4: FY2012 Leading Generic Pharmaceutical Companies by YTY Revenue Growth
  • Figure 5: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Income ($m)
  • Figure 6: FY2012 Leading Generic Pharmaceutical Companies by YTY Operating Income Growth
  • Figure 7: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Margin
  • Figure 8: Top 30 Generic Pharmaceutical Landscape Assessment - FY2012 SG&A Expense vs. Operating Expense as a Percentage of Revenue
  • Figure 9: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending ($m)
  • Figure 10: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue
  • Figure 11: FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue, YTY Change
  • Figure 12: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Expense as a Percentage of Revenue
  • Figure 13: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Debt-to-Assets Ratio
  • Figure 14: FY 2011 and FY2012, Leading Generic Pharmaceutical Companies by Cash Ratio
  • Figure 15: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by ROI
  • Figure 16: Sun Pharmaceuticals: SWOT Analysis
  • Figure 17: Sandoz: SWOT Analysis
  • Figure 18: Pharmstandard: SWOT Analysis
  • Figure 19: Teva Pharmaceuticals: SWOT Analysis
  • Figure 20: Teva Generics Sales in US vs. Rest-of-World (ROW)1, 2009-2012
  • Figure 21: Actavis: SWOT Analysis
  • Figure 22: Mylan: SWOT Analysis
  • Figure 23: Ranbaxy: SWOT Analysis
  • Figure 24: Dr. Reddy's: SWOT Analysis
  • Figure 25: Covidien: SWOT Analysis
  • Figure 26: Hospira: SWOT Analysis
Show More
Pricing